EUVIMEDEUVIMED entdecken
CrossrefInfokarte

New horizons in pharmacotherapy for Cushing’s disease and acromegaly

Maria Fleseriu, Shlomo Melmed, Artak Labadzhyan

Endocrine-Related Cancer · 2026-11-01 · 33 (11)

DOI: 10.1530/erc-26-0317 ↗
AbstractBibliografische Angaben

Abstract

Abstract The recent development of new medical therapies has transformed the Cushing’s disease and acromegaly management, offering patients more individualized and effective treatment strategies beyond surgery and addressing unmet clinical needs in persistent disease. In Cushing’s disease, newer steroidogenesis inhibitors, pituitary-directed therapies, and glucocorticoid receptor antagonists coupled with increasing recognition of disease heterogeneity have highlighted the importance of individualized therapy selection based on corticotroph adenoma characteristics, severity of hypercortisolism, comorbidities, and patient-specific priorities. Management strategies increasingly focus on normalization of biochemical markers, improvement in quality of life and metabolic outcomes, cardiovascular risk reduction, and prolongation of long-term remission. In acromegaly, the medical treatment landscape has expanded beyond monthly injectable and/or oral somatostatin receptor ligands and pegvisomant to include newer octreotide formulations, selective oral somatostatin receptor agonists, combination approaches, and a highly targeted growth hormone receptor antagonist. These developments have enabled improved biochemical control, patient convenience, and long-term disease management. Nevertheless, unmet challenges to optimal management include delayed diagnosis, treatment resistance, adverse drug effects, adenoma recurrence, and the burden of chronic disease monitoring. For both disorders, ongoing clinical trials and emerging precision medicine approaches are refining therapeutic algorithms and offering optimism for further improvements in patient outcomes. This review focuses on newly approved and investigational medical treatments for acromegaly and Cushing’s disease and their evolving role in pituitary care.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →